Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
A study to measure the safety and effectiveness of S-3304 when given in combination with conventional chemo-radiation therapy in patients with locally advanced non-small cell lung cancer.
Checked against the public recordLast updated May 2, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Shionogi
- Interventions being studied
- Drug: S-3304; Other: Chemo-irradiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
INCLUSION CRITERIA * newly diagnosed non-small cell lung cancer of stage IIIA non-resectable or of stage IIIB without pleural effusion * ECOG performance status 0-1 * adequate organ function * clinically indicated and able to receive conventional chemoradiation therapy EXCLUSION CRITERIA * patients with prior history of cancer, other than basal cell carcinoma after appropriate treatment, or prior systemic chemotherapy treatment * patients with other serious intercurrent illness including HIV/AIDS, or contraindicated for paclitaxel/carboplatin or thoracic irradiation treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Scripps Cancer InstituteLa Jolla, California
- Lombardi Cancer CenterWashington D.C., District of Columbia
- University of Kansas Cancer CenterKansas City, Kansas
- VA Medical Center-East Orange (study available to veterans only)East Orange, New Jersey
- The Cleveland ClinicCleveland, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 2, 2018. Always confirm current availability with the study team.